Literature DB >> 25908570

Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction.

Carolyn Sp Lam1.   

Abstract

Heart failure is now recognized as a progressive disease in which patients transition through the stages of being at risk of heart failure (stage A), to asymptomatic structural heart disease (stage B), to clinical manifestations of heart failure (stage C) and finally end-stage or refractory heart failure (stage D). This review outlines the key role of diabetes mellitus as a stage A risk factor for heart failure with preserved ejection fraction, and asymptomatic diabetic cardiomyopathy, referring to the presence of left ventricular diastolic dysfunction in diabetic patients without coronary artery disease, hypertension or other potential aetiologies, as an expression of stage B heart failure with preserved ejection fraction at high risk of transitioning to symptomatic stage C heart failure with preserved ejection fraction. The data presented call for better recognition of the unique phenotype of diabetic cardiomyopathy with preserved ejection fraction and elevated diastolic stiffness as a manifestation of stage B heart failure with preserved ejection fraction that should be targeted for risk management and preventive strategies.
© The Author(s) 2015.

Entities:  

Keywords:  Diabetic cardiomyopathy; diastolic dysfunction; ejection fraction; heart failure

Mesh:

Year:  2015        PMID: 25908570     DOI: 10.1177/1479164115579006

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  20 in total

1.  Diastolic function in patients with heart failure with preserved ejection fraction and atrial fibrillation: impact of diabetes.

Authors:  Ruxandra-Nicoleta Horodinschi; Camelia Cristina Diaconu
Journal:  Am J Cardiovasc Dis       Date:  2021-10-25

2.  The ceRNA Crosstalk between mRNAs and lncRNAs in Diabetes Myocardial Infarction.

Authors:  Yun Zhou; Chengjun Zhou; Lilong Wei; Chengwu Han; Yongtong Cao
Journal:  Dis Markers       Date:  2022-05-09       Impact factor: 3.464

3.  Guan Xin Dan Shen formulation protects db/db mice against diabetic cardiomyopathy via activation of Nrf2 signaling.

Authors:  Bin Zhang; Chen-Yang Zhang; Xue-Lian Zhang; Gui-Bo Sun; Xiao-Bo Sun
Journal:  Mol Med Rep       Date:  2021-05-26       Impact factor: 2.952

4.  Circulating interleukin-1β promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2.

Authors:  Zhongwei Liu; Na Zhao; Huolan Zhu; Shunming Zhu; Shuo Pan; Jing Xu; Xuejun Zhang; Yong Zhang; Junkui Wang
Journal:  Cardiovasc Diabetol       Date:  2015-09-23       Impact factor: 9.951

5.  Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia.

Authors:  Chanchal Chandramouli; Melissa E Reichelt; Claire L Curl; Upasna Varma; Laura A Bienvenu; Parisa Koutsifeli; Antonia J A Raaijmakers; Miles J De Blasio; Cheng Xue Qin; Alicia J Jenkins; Rebecca H Ritchie; Kimberley M Mellor; Lea M D Delbridge
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

Review 6.  Breakthrough in heart failure with preserved ejection fraction: are we there yet?

Authors:  Shir Lynn Lim; Carolyn Su Ping Lam
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

7.  Role of Serum Biomarkers in Early Detection of Diabetic Cardiomyopathy in the West Virginian Population.

Authors:  Adam Shaver; Alexandra Nichols; Ellen Thompson; Amrita Mallick; Kristen Payne; Chris Jones; Nandini D P K Manne; Shanmuga Sundaram; Joseph I Shapiro; Komal Sodhi
Journal:  Int J Med Sci       Date:  2016-02-05       Impact factor: 3.738

Review 8.  Present Insights on Cardiomyopathy in Diabetic Patients.

Authors:  João Soares Felício; Camila Cavalcante Koury; Carolina Tavares Carvalho; João Felício Abrahão Neto; Karem Barbosa Miléo; Thaís Pontes Arbage; Denisson Dias Silva; Alana Ferreira de Oliveira; Amanda Soares Peixoto; Antônio Bentes Figueiredo; Ândrea Kely Campos Ribeiro Dos Santos; Elizabeth Sumi Yamada; Maria Teresa Zanella
Journal:  Curr Diabetes Rev       Date:  2016

Review 9.  Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.

Authors:  Raffaele Altara; Mauro Giordano; Einar S Nordén; Alessandro Cataliotti; Mazen Kurdi; Saeed N Bajestani; George W Booz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-17       Impact factor: 5.555

10.  Role of some serum biomarkers in the early detection of diabetic cardiomyopathy.

Authors:  Amany H Abdelrahman; Iman I Salama; Somaia I Salama; Dalia M Elmosalami; Mona H Ibrahim; Eman M Hassan; Mark O Dimitry; Zahraa I Aboafya; Mohammad Gouda Mohammad; Mohamed Amin
Journal:  Future Sci OA       Date:  2021-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.